IL314068A - Preparations and methods for selective activation of cytokine signaling pathways - Google Patents
Preparations and methods for selective activation of cytokine signaling pathwaysInfo
- Publication number
- IL314068A IL314068A IL314068A IL31406824A IL314068A IL 314068 A IL314068 A IL 314068A IL 314068 A IL314068 A IL 314068A IL 31406824 A IL31406824 A IL 31406824A IL 314068 A IL314068 A IL 314068A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- methods
- signaling pathways
- selective activation
- cytokine signaling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302514P | 2022-01-24 | 2022-01-24 | |
| PCT/EP2023/051721 WO2023139293A1 (en) | 2022-01-24 | 2023-01-24 | Composition and methods for the selective activation of cytokine signaling pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314068A true IL314068A (en) | 2024-09-01 |
Family
ID=85278300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314068A IL314068A (en) | 2022-01-24 | 2023-01-24 | Preparations and methods for selective activation of cytokine signaling pathways |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230295348A1 (enExample) |
| EP (1) | EP4469163A1 (enExample) |
| JP (1) | JP2025503109A (enExample) |
| CN (1) | CN118715024A (enExample) |
| AU (1) | AU2023208426A1 (enExample) |
| CA (1) | CA3248133A1 (enExample) |
| IL (1) | IL314068A (enExample) |
| WO (1) | WO2023139293A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL305828A (en) * | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of using them |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2026039791A1 (en) * | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CN108290958B (zh) | 2015-10-02 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| GB201700345D0 (en) * | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| US11260117B2 (en) | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| JP2022511390A (ja) * | 2018-11-20 | 2022-01-31 | ユニバーシティ オブ ワシントン | 分割インターロイキン模倣体およびその使用 |
| EP3897851A2 (en) * | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
-
2023
- 2023-01-24 AU AU2023208426A patent/AU2023208426A1/en active Pending
- 2023-01-24 JP JP2024543463A patent/JP2025503109A/ja active Pending
- 2023-01-24 IL IL314068A patent/IL314068A/en unknown
- 2023-01-24 WO PCT/EP2023/051721 patent/WO2023139293A1/en not_active Ceased
- 2023-01-24 EP EP23705485.3A patent/EP4469163A1/en active Pending
- 2023-01-24 CA CA3248133A patent/CA3248133A1/en active Pending
- 2023-01-24 US US18/158,980 patent/US20230295348A1/en active Pending
- 2023-01-24 CN CN202380018600.8A patent/CN118715024A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230295348A1 (en) | 2023-09-21 |
| CN118715024A (zh) | 2024-09-27 |
| EP4469163A1 (en) | 2024-12-04 |
| CA3248133A1 (en) | 2023-07-27 |
| WO2023139293A1 (en) | 2023-07-27 |
| JP2025503109A (ja) | 2025-01-30 |
| AU2023208426A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314068A (en) | Preparations and methods for selective activation of cytokine signaling pathways | |
| IL279415A (en) | Reengineering of selective and potent interleukin mimetics | |
| EP3802578A4 (en) | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY | |
| IL276148A (en) | A preparation and method for reducing platelet count through the administration of palinabolin | |
| IL287906A (en) | Methods for the production and use of tissue-derived porous matrices | |
| IL297314A (en) | Methods for treating cytokine release syndrome | |
| IL304502A (en) | Compositions and methods for treating cytokine release syndrome | |
| GB202307609D0 (en) | Methods and composition for kras modifications | |
| IL312466A (en) | PI3K-alpha inhibitors and methods for their preparation and use | |
| IL318706A (en) | Compositions and methods for inducing proptosis | |
| IL304426A (en) | Deoxyribozymes that produce chemiluminescent signals | |
| EP4136679A4 (en) | VERTICAL DIAMOND MOSFET AND METHOD FOR PRODUCING SAME | |
| GB202306292D0 (en) | Methods and compositions for cellular therapy | |
| IL314368A (en) | Therapeutic cytokines and methods | |
| IL313889A (en) | Tryptamine preparations and methods | |
| IL325764A (en) | Designed compositions of interleukin-2 cytokine and methods of use | |
| ZA201906407B (en) | Water purification composition comprising inert particulate and purification mixture | |
| GB202308675D0 (en) | Circular rnas and methods for making the same | |
| ZA201907027B (en) | Flucarbazone sodium hemihydrate method and composition | |
| GB2613487B (en) | Methods and compositions for treating cytokine release syndrome | |
| IL326753A (en) | Synthetic Cytokine Signaling System, Method of Preparation and Uses | |
| GB202300911D0 (en) | Therapeutic compositions and methods | |
| GB202219334D0 (en) | therapeutic compositions and methods | |
| EP3886833A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA USING DEVIMISTAT | |
| HK40116214A (en) | Methods of treating the effects of cytokine storms |